Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Recent data shows a sharp rise in Hepatitis A cases across the U.S., with outbreaks linked to contaminated food, water, and specific geographic areas like Los Angeles County.
NHANES data show that among US adults, past or present Hepatitis B infection is more common in Black adults and those born outside the US compared to White adults or those born…
New recommendations focus on vaccinating adults at risk, including those who use drugs, are homeless, or have chronic liver disease, due to a major shift in how the virus spreads.
Lysosomal pathways act as checkpoints that regulate immune activation, autoantigen processing, and metabolic-immune crosstalk, driving lupus nephritis progression.
Belimumab is approved for lupus nephritis and appears more effective than anifrolumab, which is not yet approved for this condition.
Yes, the rs80213143 variant in LOC100130476 is linked to lupus nephritis risk in Chinese Han populations, with the C allele associated with more severe kidney involvement.
Yes, the CYP2C19*2 variant is linked to reduced cyclophosphamide toxicity in lupus nephritis, based on a meta-analysis showing a protective effect.
Yes, complement pathways — especially the classical and alternative pathways — contribute to kidney injury in lupus nephritis by driving inflammation and tissue damage after…
Yes, adding qiliqiangxin to your current treatment may reduce cardiovascular death and heart failure hospitalization in HFrEF, based on a large trial and meta-analysis.
No, Cimlanod does not significantly lower the chance of dying from heart failure with reduced ejection fraction based on current evidence.
Yes, Cimlanod significantly increases the risk of low blood pressure (hypotension) in patients with heart failure with reduced ejection fraction, according to a meta-analysis.
Capecitabine is not a standard treatment for triple-negative breast cancer (TNBC); trastuzumab emtansine targets HER2-positive cancer, not TNBC. Neither is considered effective…
Yes, research shows that the oral microbiome, including bacteria like Veillonella, shifts as OSCC progresses, with different patterns in early vs. advanced stages.
Yes, new treatments targeting cell death pathways like ferroptosis, cuproptosis, and autophagy are being studied for oral squamous cell carcinoma, with some showing promise in…
Yes, adding immune checkpoint inhibitors (like pembrolizumab) to chemotherapy improves event-free survival and pathologic complete response in early-stage triple-negative breast…
Yes, blood test scores like COP-MPV, mGPS, NLR, and PLR are linked to survival in OSCC, but they are not precise enough to predict individual survival time.
New immunotherapy options for triple-negative breast cancer include immune checkpoint inhibitors like pembrolizumab combined with chemotherapy, which improve survival in…
Yes, selective decontamination of the digestive tract (SDD) likely reduces hospital mortality in mechanically ventilated ICU patients, though results vary across studies.
For non-cirrhotic MASH, drugs targeting metabolism and insulin sensitivity (e.g., tirzepatide, semaglutide) work best, but lifestyle changes and weight loss are foundational.
No, a low-use wrist-strap strategy did not improve days free of delirium or coma compared to a high-use strategy in mechanically ventilated adults.
Yes, machine learning models show good accuracy for diagnosing MASH and fibrosis, with pooled AUROCs around 0.83-0.84, but they are not yet ready to replace liver biopsy in…
Yes, diaphragm ultrasound combined with the Diaphragmatic Rapid Shallow Breathing Index (D-RSBI) can predict weaning success in neurocritical patients on mechanical ventilation…
Yes, lowering triglycerides may help treat MASH by reducing liver fat and improving inflammation, but more research is needed to confirm long-term benefits.
Brolucizumab and aflibercept both improve vision in diabetic macular edema, but brolucizumab may allow longer intervals between injections while carrying a higher risk of…
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.